

Ref: A
#4
8/30/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wallner et al. Art Unit : Unknown
Serial No. : 09/730,465 Examiner : Unknown
Filed : December 5, 2000
Title : METHOD OF PROPHYLAXIS OR TREATMENT OF ANTIGEN PRESENTING
CELL DRIVEN SKIN CONDITIONS USING INHIBITORS OF THE CD2/LFA-3
INTERACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please amend the application as follows:

In the claims:

A marked-up version of the changes being made by the current amendment and an Appendix containing the pending claims, whether or not amended as they stand after entry of the present amendment, are submitted herewith.

Please amend claims 1, 4, 5, 7, 8-12, 14-22, 24-26, 31-36, 38 and 44 as follows:

A1

1. (First Time Amended) A method of preventing or treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis, comprising the step of administering to a mammal an agent which binds to LFA-3 or CD2 selected from the group consisting of a CD2 polypeptide, an LFA-3 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog, in combination with a therapy selected from the group consisting of PUVA, chemotherapy and UV light.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

July 13, 2001
Date of Deposit

Sandra Sturtevant
Signature

Sandra Sturtevant
Typed or Printed Name of Person Signing Certificate